About us Pricing ContactSubscribe

A

Andrew Blauvelt

Oregon Medical Research CenterORCID https://orcid.org/0000-0002-2633-985X

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Journal of the American Academy of Dermatology2017841 citationsFirst authorCorresponding

Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis

Journal of Investigative Dermatology2009620 citationsCorresponding

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

British Journal of Dermatology2020563 citations

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

Journal of the American Academy of Dermatology2015538 citations

Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis

Journal of Investigative Dermatology2009499 citationsCorresponding

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

British Journal of Dermatology2016450 citations

Conjunctivitis in dupilumab clinical trials

British Journal of Dermatology2019411 citations

Andrew Blauvelt · Scinovex